Table of contents:
![Russian HIV Vaccine [passed The First Phase Of Testing]](https://i.ziyadmedical.com/images/034/image-10136-j.webp "Russian HIV Vaccine [passed The First Phase Of Testing]")
Video: Russian HIV Vaccine [passed The First Phase Of Testing]
![Video: Russian HIV Vaccine [passed The First Phase Of Testing]](https://i.ytimg.com/vi/BrmXpMmvHWw/hqdefault.jpg "Video: Russian HIV Vaccine [passed The First Phase Of Testing]")
2023 Author: Abraham Higgins | [email protected]. Last modified: 2023-05-30 04:59
Russian HIV vaccine [passed the first phase of testing]
The first stage of clinical trials of an experimental vaccine against HIV infection has been successfully completed in Novosibirsk. The drug was created by specialists of the State Research Center of Virology and Biotechnology "Vector". The director of the center, Alexander Sergeev, noted that studies have shown good tolerance to the drug that stimulates a complex immune response.
![Russian HIV vaccine [passed the first phase of testing]](https://i.ziyadmedical.com/images/034/image-10136-1-j.webp "Russian HIV vaccine [passed the first phase of testing]")
Alexander Sergeev. Photo from the site kolcovo.ru /
Novosibirsk virologists have successfully carried out the first stage of clinical trials of an experimental vaccine against HIV infection, developed at the State Research Center of Virology and Biotechnology "Vector", Interfax reports with reference to the general director of the center, Alexander Sergeev.
The head of the State Research Center "Vector" said that during the research, vaccination caused a response from both the humoral and cellular links of the immune system. According to him, this is the essential difference between the domestic drug and analogs developed abroad.
Sergeev also noted that the first stage of testing showed good tolerance of the vaccine. He added that the decision to continue research should be made by the Scientific Center for the Expertise of Medicinal Products, which controls the conduct of clinical trials in the country.
As previously reported, the Russian government allocated one billion rubles in 2007 to develop a domestic vaccine against HIV infection. As a result, the specialists of the State Research Center "Vector" developed the drug "CombiVICHvac", the employees of the Institute of Immunology of the FMBA of Russia - "HIVREPOL", and the Research Institute of High-Purity Preparations together with St. Petersburg State University created the vaccine "DNA-4".
Permits for the first phase of clinical trials "CombiHIVvaca" and "DNA-4" were issued in November 2010. At that time, the developers of HIVREPOL started the second phase of testing.
